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Base resolution maps reveal the importance of
5-hydroxymethylcytosine in a human glioblastoma
Eun-Ang Raiber1, Dario Beraldi1, Sergio Martínez Cuesta1, Gordon R. McInroy2, Zoya Kingsbury3, Jennifer Becq3, Terena James3,
Margarida Lopes3, Kieren Allinson4, Sarah Field1, Sean Humphray3, Thomas Santarius5, Colin Watts5, David Bentley3 and
Shankar Balasubramanian1,2,6
Aberrant genetic and epigenetic variations drive malignant transformation and are hallmarks of cancer. Using PCR-free sample
preparation we achieved the ﬁrst in-depth whole genome (hydroxyl)-methylcytosine, single-base-resolution maps from a
glioblastoma tumour/margin sample of a patient. Our data provide new insights into how genetic and epigenetic variations are
interrelated. In the tumour, global hypermethylation with a depletion of 5-hydroxymethylcytosine was observed. The majority of
single nucleotide variations were identiﬁed as cytosine-to-thymine deamination products within CpG context, where cytosine was
preferentially methylated in the margin. Notably, we observe that cells neighbouring tumour cells display epigenetic alterations
characteristic of the tumour itself although genetically they appear “normal”. This shows the potential transfer of epigenetic
information between cells that contributes to the intratumour heterogeneity of glioblastoma. Together, our reference (epi)-genome
provides a human model system for future studies that aim to explore the link between genetic and epigenetic variations in cancer
progression.
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INTRODUCTION
Genetic and epigenetic alterations to the genome shape the
development of human malignancies. The patterns of the DNA
methylation mark 5-methylcytosine (5mC) become aberrant in
human malignancies and affect cellular functions.1 The recently
re-discovered DNA mark 5-hydroxymethylcytosine (5hmC)2, 3 is a
functionally important DNA modiﬁcation, and is an intermediate
in the process of active demethylation of 5mC. In cancers, 5hmC
patterns undergo considerable changes4 that have been linked to
genome instability5, 6 and remodelling of the DNA methylation
pattern.7 Previous studies revealed that 5hmC is consistently
found at signiﬁcantly reduced levels in various solid tumours.8–10
Indeed, epigenetic regulators such as DNA methyltransferases
(DNMT), ten-eleven-translocation (TET) proteins or isocitrate
dehydrogenases (IDH), are crucial for normal and malignant
cellular developement.11 Very few studies however, have effec-
tively mapped the distribution of 5hmC in normal or cancer
tissues. Herein, we present the ﬁrst single base resolution maps of
whole genomes, methylomes, and hydroxymethylomes for
matched human glioblastoma and tumour margin samples.
RESULTS
Enhanced (hydroxyl)-methylome sequencing reveals global
hypermethylation in tumour with loss of 5hmC
We performed whole genome sequencing at 100× coverage of
blood, tumour, and margin samples from a glioblastoma patient
(Fig. 1a) using a PCR-free library preparation.12 Total RNA
sequencing of all three samples was also performed. We
employed oxidative bisulﬁte sequencing (oxBS-seq)13 and bisulﬁte
sequencing (BS-seq) to generate high-depth (80×) sequence
coverage and built single-base resolution maps that distinguished
5mC and 5hmC modiﬁcations (Fig. 1b and Supplementary Tables 1
and 2). In the margin sample, we found levels of 50% for 5mC and
20% for 5hmC integrated over all CpGs in the genome, whereas in
the tumour, we observed global hypermethylation, with average
levels of 60% 5mC and a drastic loss of 5hmC to 1.6% (Fig. 1c).
We then assessed speciﬁc regions within the genome that were
differentially methylated between tumour and margin and
identiﬁed substantial hypermethylation in the 3′-UTRs, CpGi
shelves, exons and introns of the tumour compared to the margin
(Fig. 1d). We observed that CpGs with high levels of 5hmC in
margin tissue have correspondingly higher levels of 5mC in
tumour (Fig. 1e) suggesting that elevated 5mC sites in tumour
DNA have arisen through failure to oxidise 5mC to 5hmC.
Gene promoter (hydroxyl)-methylation and transcript levels
To investigate the possible mechanism that could account for the
loss of 5hmC, we looked for loss-of-function mutations or
epimutations and identiﬁed single base resolution (hydroxy)-
methylation changes in the promoter in connection to transcript
levels of key epigenetic regulators (Fig. 2a). Apparent loss of 5hmC in
tumours can occur through loss-of-function mutations in TET
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enzymes that oxidise 5mC to 5hmC, or inhibition of TET activity by
the oncometabolite beta-hydroxyglutarate generated by mutant
IDH1/2.14–17 IDH mutations are mutually exclusive with mutations in
TET, at least in acute myeloid leukaemia.18 No IDH mutations or loss-
of-function mutations in the TET genes were observed in the tumour
DNA for this patient. However, we observed hypermethylation at
TET2/3 gene promoters with concomitant loss of 5hmC at the same
CpGs and a corresponding reduction in TET2/3 expression in the
tumour (Fig. 2b). TET2 promoter methylation has previously been
observed in low-grade diffuse gliomas lacking IDH1/2 mutations and
provides a third mechanism to cause loss in maintenance of 5hmC
levels in the tumour. Previous literature has also linked reduced TET
function to solid and myeloid malignancies5, 19, 20 and suggested a
key role for TET in the prevention of cancer by suppressing cell
invasion21 and promoting genome integrity.5, 6 Our results in the
current glioblastoma case are consistent with these ideas.
Transcript levels in margin are related to the levels of both,
methylation and hydroxymethylation in promoters (Fig. 2c, d). The
transcript levels are low at genes whose promoters have a high
level of 5mC but a low level of 5hmC (sector 3, Fig. 2c). When
5hmC is high and 5mC is low (sector 2, Fig. 2c) transcript levels are
high. This ﬁts a model where 5mC marks silent promoters, while
5hmC and C mark active or poised promoters (Fig. 2d).22
Interestingly, even when 5mC is high and 5hmC levels shift from
low to high (sectors 3 to 4, Fig. 2c), the expression is increased.
Quantitative analysis of mRNA levels revealed that 8141 genes
(24%) were differentially expressed (logFC > 2 or logFC < −2)
between the margin and tumour (Supplementary Fig 2) with
Fig. 2e highlighting expression levels of the top ten most
differentially hydroxymethylated promoters.
Patterns of genomic variations
We analysed the mutational landscape by identifying single
nucleotide variants (SNVs) in tumour and margin using the blood
sample as a reference. Although we identiﬁed 8169 SNVs in the
tumour (Fig. 3a), the margin appeared genetically normal when
compared to blood (Supplementary Fig. 3). About 50% of all SNVs
in the tumour were C to T changes (or G to A, opposite strand),
most often in NpCpG contexts, corresponding to the mutational
signature 1A as described in Alexandrov et al. (Fig. 3b), though we
did not observe any kataegis formation.23 SNVs identiﬁed within
the coding region of several cancer genes suggest aberrations of
the RTK–RAS–PI3K signalling (mutations in PTEN, PIK3R6, and NF1)
and MYC signalling pathways (SMARCB1 and LZTR1), and have
been recently described in a genomic characterisation of IDH(+)
glioma patients.24 Additionally, complex patterns of somatic
structural variants were characteristic of the tumour (Fig. 3c). We
observed many translocation and inversion events with additional
copy number gains in chromosomes 7, 17, and 20, and copy
number losses in chromosomes 1, 6, 9, 10, 11, 18, and 22. Notably,
the epigenetic modiﬁers TET1 (chromosome 10) and DNMT1/3B
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Fig. 1 Cytosine modiﬁcation landscape of all CpG sites (n= 2.7 × 107) in a glioblastoma patient. a Hematoxylin and eosin (H&E) staining of the
margin (top) and tumour (bottom) samples (see Methods). b Base resolution outlook of 5mC and 5hmC levels, nucleotide alterations and
changes in transcript levels between margin (M) and tumour (T) in the ATRX gene. The close view highlights 32 bp of the CpG island
(chrX:77041003-77041725) located in the 5′-UTR region (middle) and average levels of modiﬁcation across the 1 kb promoter (chrX:77041719-
77042719) (right). Transcript levels (left) are displayed in transcripts per million (TPM). c Combination of BS and oxBS-seq reveals a severe
decrease of 5hmC in tumour accompanied by an increase of 5mC, however BS-seq only cannot distinguish between 5mC and 5hmC, and
would suggest tumour hypomethylation. Distribution of 5mC and 5hmC in the margin and tumour samples d across genomic regions and e
in a sample of 105 CpG sites colour-coded according to the level of 5hmC in the margin
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(chromosomes 19 and 20) were haploid and polyploid in tumour
respectively, which suggests a connection between the observed
hypermethylation (DNMT polyploidy) and 5hmC loss (diminished
TET function) in the tumour.
Links between genomic and epigenomic changes
To investigate links between genetic and epigenetic mutations,
we identiﬁed SNV sites resulting from the mutation of cytosine to
any other base in the tumour, and studied their methylation and
hydroxymethylation status in the margin (Fig. 4a). We found that
SNV sites were signiﬁcantly more methylated in the margin
compared to non-SNV sites (Mann–Whitney test, p-value <
2.2e–16, two-sided). Conversely, we found that SNV sites were
signiﬁcantly less hydroxymethylated in the margin compared to
non-SNV sites (Mann–Whitney test, p-value < 2.2e–16, two-sided)
with no apparent differences for all types of cytosine mutations
(i.e. C to, C to G, or C to A) (Fig. 4b). Regions identiﬁed to be of
different ploidy in margin and tumour (Fig. 3c) did not show
differences in modiﬁcation levels (Fig. 4c).
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Fig. 2 Overview of the relationship between genetic changes, promoter 5mC/5hmC levels and gene expression. a Summary of the molecular
details of the genes involved in the turnover of cytosine modiﬁcations. Differential transcript levels between tumour and margin (log2FC
where FC= (TPMtumour + 0.01)/(TPMmargin + 0.01)) and mean transcript levels ((log2(TPMtumour + 0.01) + (log2(TPMmargin + 0.01))/2), SNVs (1:
presence and 0: absence), CNVs (↑: gain of copies, 0: diploid and ↓: loss of copies and LOH: loss of heterozygosity), promoter CpG counts, and
promoter 5mC and 5hmC levels (%) in margin (M) and tumour (T), which are colour-coded as shown in the legend. Genes bearing genomic
alterations in glioma progression24 were also examined (Supplementary Fig. 1). b Average and base resolution maps of 5mC and 5hmC levels
and changes in transcript abundance between margin and tumour in the promoter region (1 kb upstream of the transcription start site) of the
TET2 (chr4:106066031-106067031, 22 CpG sites) and TET3 (chr2:74272449-74273449, 6 CpG sites) genes. c Cytosine modiﬁcations and changes
in transcript levels across all gene promoters containing CpG sites (n= 18,653) in margin. Promoters are divided into four sectors according to
the levels of 5mC and 5hmC: sectors {1, 2} and {3, 4} contain low and high levels of 5mC according to the ﬁrst and third terciles (3.2 and 23.2%)
of the %5mC distribution respectively (horizontal axis). The median level of 5hmC (7.4%) is used to separate low and high 5hmC levels (vertical
axis). The inset box plot displays the transcript levels for each sector. d Promoters are divided into three types depending on whether 5mC,
5hmC or C is more abundant within the promoter. The inset box plot illustrates the transcript levels for each promoter type. e Relationship
between differential transcript levels (log2FC) and differences in 5hmC levels between tumour and margin in gene promoters containing more
than 10 CpG sites (n= 15,716). The top ten promoters with larger changes in 5hmC levels are labelled
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Tumour purity was estimated to be 71% by genetic analysis and
60% by immunohistochemistry (see Methods). Based on tumour
purity, we calculated the expected global level of 5hmC to have a
lower limit of 7% (Table 1), assuming complete loss of 5hmC in the
tumour. We measured actual levels of 5hmC in the tumour sample
to be 1.6%, more than four-fold lower than the estimated lower
limit.
DISCUSSION
We used a PCR-free approach to generate accurate methylomes
and hydroxymethylomes. Importantly, our ability to resolve 5mC
and 5hmC signals reveals global hypermethylation in the tumour,
contrary to the appearance of global hypomethylation when using
only BS-seq, which actually measures the sum of 5mC and 5hmC
and fails to resolve the two signals. Global hypermethylation has
just recently also been reported for kidney cancer using an
alternative method that was able to distinguish 5mC from 5hmC.25
While genome-wide hypomethylation26, 27 is somewhat regarded
as an epigenetic hallmark of tumorigenesis and has been
implicated in the evolution of human glioblastomas,28 our results
suggest that data obtained from bisulﬁte-only approaches need to
be re-interpreted.
TET2 promoter methylation has previously been observed in
low-grade diffuse gliomas lacking IDH1/2 mutations and provides
a third mechanism to cause loss in maintenance of 5hmC levels in
the tumour. Previous literature has also linked reduced TET
function to solid and myeloid malignancies5, 19, 20 and suggested
a key role for TET in the prevention of cancer by suppressing cell
invasion21 and promoting genome integrity.5, 6 Our results are
consistent with this mechanism in the current glioblastoma case.
5mCpG sequences have previously been reported to be
mutational hotspots in human genetic disease and cancer-
relevant genes, probably through the deamination of 5mC to
T.29 Our data show that 5mCpG sites are predisposed to
mutations, whereas 5hmCpG sites are protected from mutations
during tumorigenesis, mirroring observations recently reported for
brain and kidney cancer, and myeloid leukaemias.30 Interestingly,
the ‘protection’ at 5hmCpG sites holds for all types of cytosine
mutations (C to T, C to G, or C to A).
Our observation that 5hmC levels in the tumour are signiﬁcantly
lower than the estimated lower limit suggests a loss of 5hmC in
the genetically “normal” cells within the tumour mass. Earlier
studies reported that genome-wide methylation changes in
tumours can be acquired in adjacent normal cells linking 5mC
to ﬁeld defects.31–33 The concept of ﬁeld defects34 has been used
to describe the early events in the stepwise transformation of the
cancer that can potentially lead to further oncogenic changes. To
the best of our knowledge, this is the ﬁrst observation of acquired,
early changes in 5hmC in proximal cells.
Accurate, high resolution whole genome maps have allowed us
to discern a role for 5hmC in protecting the genome against
somatic mutations, observe global hypermethylation in a tumour
and provide new evidence that associates 5hmC with epigenetic
transformation in genetically normal cells adjacent to the tumour.
Epigenetic analysis of 5hmC, in addition to 5mC, may foster
diagnostic approaches in the future.
METHODS
Clinical events
A 71-year old woman underwent supra-total resection of a right
frontal intrinsic tumour with maximum diameter of the enhancing
component of 19 mm, surrounded by only minimal oedema.
Histological examination conﬁrmed the diagnosis of glioblastoma
Fig. 3 Genetic variation landscape of the tumour sample. a 8169 somatic variants, mostly C to T transitions, identiﬁed when comparing the
tumour and margin samples. b The 5′ and 3′ nucleotide context around the somatic variants in tumour suggests that most mutations occur in
CpG sites. c At the top, genomic location of CNVs: polyploid regions (Gain) in red, diploid regions (Ref ) in black, haploid regions (Loss) in green,
and loss of heterozygosity (LOH) in blue. In the middle, B-allele ratio plot. At the bottom, genomic translocations (blue) and inversions (purple)
in the tumour
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multiforme (WHO 9440/3). Tissue collection protocols were
compliant with the UK Human Tissue Act 2004 (HTA License ref.
12315) and approved by the Local Regional Ethics Committee
(LREC ref. 04/Q0108/60). Informed consent was obtained from the
patient before surgery. Surgical samples were taken from the
enhancing tumour mass and corresponding non-enhancing
margin using advanced surgical techniques described pre-
viously.35 After rapid recovery she underwent six weeks of
radiotherapy (60Gy in 30 fractions) with concurrent temozolomide
(TMZ) treatment. She then completed two cycles of adjuvant TMZ
treatment during 12 weeks. This was stopped because of poor
tolerance. While her 9-months post-operative scan was clear of
tumour, her 11-months check demonstrated tumour recurrence
and she died 3 months later from the combination of tumour
progression and thromboembolic complications.
Samples
Brain tumour biopsies were ﬁxed in 10% formalin and embedded
in parafﬁn wax from which 4-µm-thick sections were cut and
stained with haematoxylin and eosin (H&E). The diagnosis of
glioblastoma multiforme (WHO 9440/3) was made by light
microscopical examination of H&E-stained sections. Glioblastoma
was deﬁned by WHO-2016 criteria of an inﬁltrative astrocytoma
with proliferative activity, necrosis and/or microvascular
proliferation.
To determine the IDH1 status by immunohistochemistry, the 4-
µm-thick sections were dried at 60 °C for 2 h and further processed
on a Bond Max (Leica). After a 60-min pre-treatment with cell
conditioner 2 (pH 6) the slides were incubated with 1:80 diluted
H09 anti-IDH1 R132H antibody (Dianova, Hamburg, Germany) at
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Fig. 4 Link between genetic variation and cytosine modiﬁcations. a Analysis of 5mC and 5hmC levels within the margin CpG sites that are
mutated in tumour (SNVs). b Differences in modiﬁcation levels depending on the mutated base in tumour: C>T (n= 2527), C>G (n= 32) and
C>A (n= 51). c Distribution of modiﬁcation levels in margin and tumour in regions with gain or loss of copies, diploid (Ref ) or loss of
heterozygosity (LOH) according to the CNV analysis of the tumour sample (Fig. 3c)
Table 1. Overall cytosine modiﬁcation levels of all CpG sites (n= 2.7 ×
107) in a glioblastoma patient
Sample % 5mC % 5hmC
Margin 52.1 17.5
Tumour 63.5 1.6
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room temperature for 30 min. A standard 3,3’-diaminobenzidine
(DAB) detection kit was used for chromogenic detection. The
common IDH1 mutation (R132H) was not detected.
To determine the MGMT promoter methylation, H&E-stained
slides were reviewed and neoplastic cell-rich tissue was dissected
from consecutive unstained sections. DNA was extracted from the
dissected tissue using the QIAamp DNA FFPE Tissue Kit (Qiagen)
and was bisulphite-converted using the EpiTect Bisulphite Kit
(Qiagen). The MGMT promoter methylation was determined by
pyrosequencing of four CpG sites (CpGs 76-79) in exon 1 of the
MGMT gene using the CE-Marked therascreen MGMT Pyro Kit on a
Pyromark Q24 System (Qiagen). Signiﬁcant levels of MGMT
promoter methylation were not detected.
To determine the tumour cell purity of the samples, H&E-
stained slides were reviewed and cell counting was performed on
multiple high-powered ﬁelds. The tumour cell purity of both the
tumour and its margin was assessed by a pathologist prior to
molecular proﬁling. No tumour cells were detected in the margins
and the tumour was estimated to consist of 60% tumour cells.
DNA and RNA extraction for sequencing
Each tumour and margin sample was frozen to −80 °C immedi-
ately on collection. The frozen samples were then defrosted and a
50mg portion taken for DNA/RNA extraction. The samples were
homogenised and then divided for DNA and RNA extraction. DNA
extraction of both tissues and blood was performed using the
QIAGEN DNeasy Blood and Tissue Kit, RNA extraction was
performed using the QIAGEN RNeasy Mini Kit. Quantiﬁcation
was performed using the Qubit quantiﬁcation assay. The tumour/
normal pair used in this study was the sample judged most pure
by comparison with blood DNA using whole genome sequencing.
PCR-free oxBS and BS library preparation and sequencing
PCR-free ReBuilT libraries for bisulﬁte sequencing were generated
following our previously published method.12 For the generation
of PCR-free libraries for oxBS, libraries were oxidised (TrueMethyl
Kit from CEGX) prior to bisulﬁte treatment. In brief, 350 and 175 ng
of sonicated DNA from tumour and margin respectively were end
repaired and dA-tailed before ligation of customized adapter pair.
After (oxidation)-bisulﬁte treatment, degraded fragments were
recovered through primer extension before dA-tailing and second
adapter ligation. Libraries were subsequently immobilized on
streptavidin coated magnetic beads, washed with binding buffer,
eluted with 50 mM NaOH at 60 °C for 15 min. BS and oxBS-seq
libraries were sequenced on an Illumina HiSeq 2500 platform, V4
chemistry, 2x101+7 index cycles.
RNA-seq library preparation and sequencing
Libraries of the tumour and margin samples were prepared using
TruSeq RNA Access kit (Illumina), using an input of 40 and 20 ng
respectively. The libraries were sequenced for 2 × 75 cycles on
HiSeq 2500 in Rapid mode achieving an average coding coverage
of 108x (F2), 136X (F3), 277x (M1), 272x (M3).
Computational analysis
Code availability. Details of the analysis are available in the
manuscript's GitHub repository (https://github.com/sblab-
bioinformatics/epigenetics-of-glioblastoma).
DNA-seq data analysis. Libraries were sequenced on an Illumina
HiSeq 2500 platform. Alignment to the human reference genome
GRCh37 and quality control was performed using Isaac.36
Identiﬁcation of somatic SNVs and small somatic indels (<50 bp)
was performed by Strelka.37 Large copy number variants and
structural variants were respectively called with Canvas38 and
Manta.39 The full workﬂow can be found in the Tumour Normal
application of the Illumina BaseSpace platform (http://support.
illumina.com/content/dam/illumina-support/help/BaseSpace_App
_TumorNormal_v2/tumor-normal-v2-help.htm).
BS and oxBS-seq data analysis. Raw reads were trimmed to
remove adapter sequences ligated to the 3'-end using cutadapt40
and aligned to the human reference genome hg19 using
bwameth,41 a wrapper around bwa-mem.42
RNA-seq data analysis. As above, reads were trimmed to remove
adapter sequences using cutadapt and aligned to reference
transcripts obtained from Ensembl43 and quantiﬁed using
kallisto.44
Tumour purity estimation. The copy number variant analysis
using Canvas38 provided us with an estimate of 71% purity of the
tumour sample.45 This software Q1calculates coverage and tumour
SNV allele frequencies at heterozygous germline positions along
the genome. It then assigns copy numbers per genomic regions
and infers genome-wide ploidy and purity by ﬁtting the data to
expected models for each copy number state given purity and
diploid coverage level combinations. Purity is then derived from
the best ﬁtting model.
Data availability
Data are available in the ArrayExpress database (www.ebi.ac.uk/
arrayexpress) under accession number E-MTAB-5171
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